PANBELA THERAPEUTICS INVESTOR ALERT - Kuznicki Law PLLC Investigates Panbela Therapeutics, Inc. - PBLA
May 04 2022 - 5:30PM
Business Wire
Kuznicki Law PLLC is investigating the proposed sale of Cancer
Prevention Pharmaceuticals, Inc. to Panbela Therapeutics, Inc.
(“the Company”) (NasdaqCM: PBLA). Under the terms of the proposed
transaction, holders of Panbela common stock are expected to own
only approximately 59% of the post-merger holding company.
If you would like to discuss your legal rights regarding the
proposed sale, you may, without obligation or cost to you, contact
us toll free at 833-938-0905, via email (dk@kclasslaw.com), or
visit https://kclasslaw.com/cases/ma/nasdaqcm-pbla/ to learn
more.
Kuznicki Law PLLC is committed to ensuring that companies adhere
to responsible business practices and engage in good corporate
citizenship. The firm seeks recovery on behalf of investors who
incurred losses when false and/or misleading statements or the
omission of material information by a Company lead to artificial
inflation of the Company’s stock. Attorney advertising. Prior
results do not guarantee similar outcomes.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220504006268/en/
Kuznicki Law PLLC Daniel Kuznicki, Esq. Email: dk@kclasslaw.com
Phone: (347) 696-1134 Cell: (347) 690-0692 Fax: (347) 348-0967
https://kclasslaw.com
Panbela Therapeutics (NASDAQ:PBLA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Panbela Therapeutics (NASDAQ:PBLA)
Historical Stock Chart
From Sep 2023 to Sep 2024